In China, gastric cancer is the second most common cause of cancer-related death, after lung cancer. At present, the morbidity and mortality rates of gastric cancer are increasing, and targeted therapy for gastric cancer has become a research hotspot. Herein, we report a patient with multiple metastases from advanced gastric cancer. After identifying MET gene amplification, initial treatment induced regression of the tumor. However, in later stages, due to the overexpression or mutation of HER-2, KRAS, TP53, and other genes, the targeted drug therapy became ineffective, and the disease progressed rapidly, leading to the death of the patient.
基金：
Hebei Provincial Key Research Projects10.13039/501100015286
第一作者机构：[1]Hebei Med Univ, Dept Gastroenterol, Hosp 4, Shijiazhuang, Hebei, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[1]Hebei Med Univ, Dept Gastroenterol, Hosp 4, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714)：
Zhang Xin,Zhang Xinran,Geng Dandan,et al.Targeted therapy for multiple gene mutations in multiple metastases of advanced gastric cancer: a case report[J].FRONTIERS IN ONCOLOGY.2023,13:doi:10.3389/fonc.2023.1257011.
APA：
Zhang, Xin,Zhang, Xinran,Geng, Dandan,Zhao, Chenguang,Wang, Yingnan...&Zhang, Fengbin.(2023).Targeted therapy for multiple gene mutations in multiple metastases of advanced gastric cancer: a case report.FRONTIERS IN ONCOLOGY,13,
MLA：
Zhang, Xin,et al."Targeted therapy for multiple gene mutations in multiple metastases of advanced gastric cancer: a case report".FRONTIERS IN ONCOLOGY 13.(2023)
